Ensysce Biosciences, Inc. 8-K

What Happened
Ensysce Biosciences, Inc. filed an 8‑K reporting that director Lee Rauch submitted her resignation effective March 24, 2026. The filing also discloses that, as the company pursues strategic alternatives, the Compensation Committee recommended — and the Board approved on March 27, 2026 — short-term severance/retention measures to keep three managers and CFO Michael (or Mr.) Humphrey through the transaction period. The measures increase Mr. Humphrey’s retention from 6 months to 9 months and create three‑month severance packages for the other managers. Total estimated cost is approximately $205,475. Ms. Rauch voted against the packages (she had voted no on March 23, 2026) and had previously expressed other disagreements with Board actions.

Key Details

• Director resignation: Lee Rauch, effective March 24, 2026; she served on the Audit and Compensation Committees and chaired the Nominating & Corporate Governance Committee.
• Retention/severance: three managers to receive three-month severance; CFO retention increased from 6 to 9 months.
• Cost and conditions: total estimated cost ≈ $205,475; payments apply only if the recipients are not retained in a strategic transaction (or within one year following) and require a full release of claims and reconfirmation of restrictive covenants.
• Board action timeline: Compensation Committee recommended the packages; Board approved on March 27, 2026; Rauch voted against on March 23.

Why It Matters
For investors, the filing signals a governance change (loss of a board member and potential committee reshuffling) and a management-retention step tied to the company’s strategic review. The estimated $205k cost is relatively modest but represents an added potential cash obligation tied to a strategic transaction outcome and specific release conditions. Rauch’s dissent may be of interest to shareholders watching board dynamics during the strategic alternatives process.